A Comprehensive Safety Evaluation of Trabectedin and Drug–Drug Interactions of Trabectedin-Based Combinations
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Comprehensive Safety Evaluation of Trabectedin and Drug–Drug Interactions of Trabectedin-Based Combinations
Authors
Keywords
Soft Tissue Sarcoma, Aprepitant, Trabectedin, Pegylated Liposomal Doxorubicin, Recurrent Ovarian Cancer
Journal
BIODRUGS
Volume 28, Issue 6, Pages 499-511
Publisher
Springer Nature
Online
2014-09-10
DOI
10.1007/s40259-014-0100-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trabectedin for advanced soft tissue sarcomas: a single institution experience
- (2014) Ioannis Gounaris et al. Future Oncology
- Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
- (2014) Takafumi Ueda et al. INVESTIGATIONAL NEW DRUGS
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
- (2013) B. L. Samuels et al. ANNALS OF ONCOLOGY
- Trabectedin in patients with metastatic soft tissue sarcoma
- (2013) Sophie Schur et al. ANTI-CANCER DRUGS
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
- (2013) Jean-Yves Blay et al. BMC CANCER
- Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
- (2013) Sabino Strippoli et al. BMC Complementary and Alternative Medicine
- Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
- (2013) A L Cesne et al. BRITISH JOURNAL OF CANCER
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Safety evaluation of trabectedin in treatment of soft-tissue sarcomas
- (2013) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
- (2013) Jean Yves Blay et al. Future Oncology
- The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)
- (2013) F. Ploner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Mode of action of trabectedin in myxoid liposarcomas
- (2013) S Di Giandomenico et al. ONCOGENE
- Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature
- (2013) Danilo Galizia et al. ONCOLOGY RESEARCH
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
- (2012) Federica Grosso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
- (2012) Bradley J. Monk et al. CURRENT PHARMACEUTICAL DESIGN
- The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
- (2012) Daniela D’Angelo et al. EUROPEAN JOURNAL OF CANCER
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
- (2012) Axel Le Cesne et al. INVESTIGATIONAL NEW DRUGS
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
- (2012) Ioana Abraham et al. Marine Drugs
- Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option
- (2012) Patrick Schöffski et al. ONKOLOGIE
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
- (2011) A. Gronchi et al. ANNALS OF ONCOLOGY
- Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
- (2011) Claudia Lebedinsky et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
- (2011) Juliette Thariat et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
- (2011) R. Thertulien et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment
- (2011) P. Allavena et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
- (2011) Françoise Ducimetière et al. PLoS One
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) P. G. Casali et al. ANNALS OF ONCOLOGY
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
- (2010) G. Germano et al. CANCER RESEARCH
- Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
- (2010) Q. Chu et al. CLINICAL CANCER RESEARCH
- Trabectedin therapy for sarcomas
- (2010) Paolo G Casali et al. CURRENT OPINION IN ONCOLOGY
- Trabectedin
- (2010) Natalie J. Carter et al. DRUGS
- Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
- (2010) Luis Paz-Ares et al. INVESTIGATIONAL NEW DRUGS
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
- (2009) J. M. Del Campo et al. ANNALS OF ONCOLOGY
- Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
- (2009) F. Grosso et al. ANNALS OF ONCOLOGY
- Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours
- (2009) C. Sessa et al. EUROPEAN JOURNAL OF CANCER
- Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage
- (2009) Todd A. Theman et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin
- (2009) M. K. Chuk et al. ONCOLOGIST
- A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
- (2008) M. von Mehren et al. ANNALS OF ONCOLOGY
- Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
- (2008) Wells A. Messersmith et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
- (2008) J.-Y. Blay et al. CLINICAL CANCER RESEARCH
- Role of homologous recombination in trabectedin-induced DNA damage
- (2008) M. Tavecchio et al. EUROPEAN JOURNAL OF CANCER
- Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
- (2008) C. Sessa et al. EUROPEAN JOURNAL OF CANCER
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
- (2008) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- Second-line randomized trials in epithelial ovarian cancer
- (2008) J.B. VERMORKEN INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity
- (2007) Jin Kyung Lee et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started